CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.
Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM, Kufe DW, Vonhoff DD, Iwami T, Kawabe T.
Sakakibara K, et al. Among authors: hasegawa y.
Blood. 2011 Oct 6;118(14):3922-31. doi: 10.1182/blood-2011-01-333138. Epub 2011 Aug 12.
Blood. 2011.
PMID: 21841164
Free article.